Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Moxisylyte. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.97 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | PKM | P14618 | 1/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxisylyte SCHEMBL456546 | 0.99 | ADRA1D (1.00) | SMN1; SMN2BLMADRA1DADRA1AADRA1B | |
| Moxisylyte SCHEMBL1649830 | 0.96 | ADRA1D (0.95) | SMN1; SMN2BLMADRA1DADRA1AADRA1B | |
| Moxisylyte SCHEMBL6398989 | 0.93 | ADRA1D (0.88) | SMN1; SMN2BLMADRA1DADRA1AADRA1B | |
| Iproxamine SCHEMBL120331 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2BLMADRA1DADRA1AADRA1B | |
| Iproxamine SCHEMBL1815834 | 0.85 | ADRA1D (0.76) | SMN1; SMN2BLMADRA1DADRA1AADRA1B | |
| SCHEMBL5235884 | 0.83 | ADRA1D (0.72) | SMN1; SMN2BLMADRA1DADRA1AADRA1B | |
| SCHEMBL8924260 | 0.83 | CYP1A2 (0.72) | SMN1; SMN2BLMADRA1DADRA1AADRA1B | |
| SCHEMBL12013918 | 0.83 | CYP1A2 (0.72) | SMN1; SMN2BLMADRA1DADRA1AADRA1B | |
| SCHEMBL4695767 | 0.82 | ADRA1D (0.71) | SMN1; SMN2BLMADRA1DADRA1AADRA1B | |
| SCHEMBL4696868 | 0.82 | ADRA1D (0.71) | SMN1; SMN2BLMADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| US-11865217-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2024-01-09 | — | — | US | claimed |
| EP-4106816-A1 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | North Atlantic Holdings LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220387343-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2022-12-08 | — | — | US | claimed |
| US-11446257-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2022-09-20 | — | — | US | claimed |
| WO-2008126088-A2 | ANTI-PYRETIC VASODILATORS | ZACHAR ORON (IL) | 2008-10-23 | — | — | WO | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5561154-A | MUSCLE RELAXANTS | INSTITUT DE RECHERCHES CHIMIQUES ET BIOLOQUES APPLIQUEES IRCEBA (FR) | 1996-10-01 | — | — | US | claimed |
| EP-0728479-A1 | Deacetyl moxisylyte in the treatment of acute urinary retention | INSTITUT DE RECHERCHES CHIMIQUES ET BIOLOGIQUES APPLIQUEES (IRCEBA) (FR) | 1996-08-28 | — | — | EP | claimed |
| US-5451609-A | DEACETLY MOXISYLYTE | INSTITUT DE RECHERCHES CHIMIQUES ET AL (FR) | 1995-09-19 | — | — | US | claimed |
| US-5182270-A | Inclusion compound with dimethyl-beta-cyclodextrin | IOLAB CORPORATION (US) | 1993-01-26 | — | — | US | claimed |
| EP-0031184-A1 | Process for the preparation of 4-(2-(dimethylamino)-ethoxy)-2-methyl-5-(1-methylethyl)-phenol esters and their salts | BLASCHIM S.p.A. (IT) | 1981-07-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | ADRA1D 94/4885ADRA1A 159/4885ADRA1B 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.